Elevation Oncology(ELEV) - 2024 Q1 - Quarterly Results

Recent Business Achievements Exhibit 99.1 Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements -- Enrollment ongoing in Phase 1 clinical trial of EO-3021 in the U.S. and Japan; expect to announce initial safety and efficacy data by mid-3Q 2024, with additional data in 1H 2025 -- -- Presented preclinical proof-of-concept data for HER3-ADC program at AACR Annual Meeting; on-track to nominate development candidate in 2H 2024 -- -- Raised $44.2 million year ...